COMPASS Pathways (5Y6) AI Stock Analysis

Company Guidance

Compass expects to complete its rolling NDA submission in the next two weeks, with the National Priority Voucher providing a one-to-two-month review target, a reasonably wide distribution around a median of around 60 days, and the potential for a complete approval within that 30-60-day timeline; the company is preparing to launch COMP360 in the first half of 2027 and expects $444 million of cash on hand as of September 30th to carry it well through the launch and into 2028. More than 93% of the U.S. population lives in states that have stated that they intend to reschedule within 30 days after federal DEA rescheduling, which is subject to the 90-day statutory timeline, while CPT Category III codes are anticipated to take 12-18 months to transition to Category I; REMS training is expected to take one to two hours, monitoring is expected to involve one primary monitor and two total healthcare providers, and repeat dosing would be targeted after one or two initial administrations with episodic dosing per physician decision. The company expects COMP360 to involve just a few treatments a year, compared with 36-54 required per the SPRAVATO label, and expects buy-and-bill volume to ramp from not being huge out of the gate to something very similar to SPRAVATO’s 30%-40% range of volume, potentially even surpassing it; planned 2027 launch metrics include REMS certifications, prescriptions, prescribers, and payer access.